| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Minerva Neurosciences, Inc$4.72
0 (0%)
D 35Pipeline Score Overvalued Pharma · Clinical
Market Cap
245.06 M
EPS
-29.16
P/E Ratio
-
Value Trade
515.11 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
5.25 M
Operating CF
-5.43 M
Total Assets
94.03 M
Total Liabilities
343.08 M
Equity
-254.01 M
D/E Ratio
12,345
-3.13 %
Week
-26.02 %
1 Month
-14.89 %
3 Month
22.04 %
6 Month
-78.54 %
5 Year
-89.04 %
All Time
Cash Data
Cash Position
78.06 M
Monthly Burn
1.81 M
Runway
41.2 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
235.01 K
52 Week Range
1.35 - 12.46
% held by Insiders
20.44 %
% held by Institutions
79.36 %
Enterprise Value
231.85 M
Total Shares
43.85 M
Short %
5.73 %
Float Shares
33.24 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Minerva Neurosciences, Inc
439Total events
5Upcoming
105Tier-1 (high impact)
2014 – 2030Coverage
Upcoming catalysts 5
Event history 434
Jun 4, 2026
◆Oral PresentationPresentation
Minerva Neurosciences to participate in 2026 Jefferies Global Healthcare Conference fireside chat
Jun 1, 2026
▲Trial InitiationRoluperidoneTrial
Phase 3 confirmatory trial MIN-101C19 initiated
negative symptoms of schizophreniasource ↗
May 5, 2026
▲Trial InitiationRoluperidoneTrial
Confirmatory Phase 3 trial of roluperidone initiated
negative symptoms of schizophreniasource ↗
May 5, 2026
▲First Patient DosedRoluperidoneTrial
First patient screened in confirmatory Phase 3 trial
negative symptoms of schizophreniasource ↗
Apr 21, 2026
◆Management ChangeCorporate
Jim O'Connor appointed as Chief Business Officer and General Counsel, effective April 21, 2026
Q2 2026
◆Trial InitiationRoluperidoneTrial
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia planned for Q2 2026
negative symptoms of schizophreniasource ↗
Mar 31, 2026
▲First Patient DosedRoluperidoneTrial
First patient screened in global Phase 3 confirmatory trial of roluperidone
negative symptoms of schizophreniasource ↗
Mar 25, 2026
▲Oral PresentationRoluperidonePresentation
Presentation of open-label safety trial data for roluperidone co-administered with olanzapine at SIRS 2026
negative symptoms of schizophreniasource ↗
Mar 25, 2026
◆Enrollment UpdateRoluperidoneTrial
Confirmatory Phase 3 trial now enrolling
negative symptoms of schizophreniasource ↗
Mar 18, 2026
◆Oral PresentationPresentation
Minerva Neurosciences presentation at Stifel 2026 Virtual CNS Forum
Drug Pipeline Intelligence
D35
Pipeline Score $145M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.6x
rNPV / MCap Top 47%
Micro Cap (rank 484 of 911)
Percentile RankMinerva Neurosciences, Inc faces pipeline headwinds (35/100), with $580M risk-adjusted pipeline value, led by MIN-117 in Major Depressive Disorder (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIN-117 Small molecule | Major Depressive Disorder | Phase 2 | NCT03446846 | 12% | $308M | COMPLETED | 360 | - | - | Dec 13, 2019 | - | Dec 17, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
roluperidone | negative symptoms of schizophrenia | — | 2026-03-26 | no significant safety concerns or adverse effects | Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 Read More | |
roluperidone | negative symptoms of schizophrenia | — | 2026-03-26 | no significant safety concerns or adverse effects | Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 Read More | |
roluperidone | negative symptoms of schizophrenia | — | 2026-03-26 | no significant safety concerns or adverse effects | Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NERV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NERV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NERVMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences has established a Scientific Advisory Board to guide the Phase 3 trial of roluperidone, aimed at treating negative symptoms of schizophrenia. The board comprises experts in psychiatry and neuroscience, enhancing the company's research and development strategy. The trial is crucial as it targets an area with no approved therapies in the U.S.
Read more →NERV▼ -9%on this news
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva Neurosciences, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference scheduled for June 2-4, 2026, in New York. CEO Remy Luthringer will represent the company, which specializes in therapies for central nervous system disorders. Attendees can arrange meetings with the Minerva team through Jefferies representatives. A replay of the presentation will be accessible for 90 days post-event.
Read more →NERVMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous ope
Minerva Neurosciences reported its first quarter 2026 financial results, announcing the initiation of a confirmatory Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia. The trial aims to confirm the drug's effectiveness and will enroll approximately 380 adults. The company noted a significant financial loss for the quarter, attributed to rising R&D and administrative expenses. Despite these financial challenges, the company remains optimistic about the unique potential of roluperidone in addressing unmet medical needs in mental health.
Read more →NERVMinerva Announces Leadership Transition
Minerva Neurosciences has appointed Jim O'Connor as Chief Business Officer, effective April 21, 2026, following the departure of President Geoff Race. Race will continue as a consultant, having significantly contributed to the company's development since 2010. O'Connor aims to advance Minerva's strategy and lead the upcoming Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia.
Read more →NERV▼ -5.7%on this newsshared move
Minerva Announces Leadership Transition Jim O'Connor joins as Chief Business Officer and General Counsel
Minerva Neurosciences has announced a leadership transition, appointing Jim O'Connor as Chief Business Officer and General Counsel. This change follows the departure of Geoff Race, the company's former President, who will continue to contribute as a consultant. O'Connor's extensive background in legal and business leadership positions him to advance Minerva's initiatives, particularly in the development of roluperidone for treating negative symptoms of schizophrenia. The company is optimistic that this transition will enhance their strategic direction and assist in upcoming clinical trials.
Read more →NERV▼ -7.1%on this newsshared move
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences has initiated a global Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia. This trial follows positive results from earlier studies and aims to enroll approximately 380 patients. Efficacy data is expected in the second half of 2027, addressing a significant unmet medical need in this patient population.
Read more →NERVMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Minerva Neurosciences presented positive data from its open-label safety trial of roluperidone co-administered with olanzapine at the SIRS 2026 conference. The trial showed no significant safety concerns or adverse effects, supporting the ongoing Phase 3 trial, which is currently enrolling participants. Topline results are anticipated in late 2027.
Read more →NERV▲ +5.3%on this news
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences, Inc. will participate in The Stifel 2026 Virtual CNS Forum on March 17-18, 2026. CEO Remy Luthringer will represent the company during the event. Interested parties can arrange virtual meetings through their Stifel representatives. A replay of the presentation will be available for ninety days post-event.
Read more →NERV▼ -8.1%on this newsshared move
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2
Minerva Neurosciences announced its financial results for the fourth quarter and fiscal year 2025, including a planned initiation of a confirmatory Phase 3 trial for roluperidone targeting negative symptoms of schizophrenia in Q2 2026. The company experienced a considerable net loss for Q4 2025, amounting to $283.7 million, which has raised concerns regarding its financial stability. Minerva also reported an increase in total liabilities, which amounted to $233.8 million for the year. Despite these challenges, the recent $80 million financing bolsters its capacity to advance clinical development.
Read more →NERVMinerva Neurosciences to Participate in The Citizens Life Sciences Conference
Minerva Neurosciences, Inc. will participate in The Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL. CEO Remy Luthringer will represent the company, which is focused on CNS disorder therapies. A replay of the presentation will be accessible for 90 days post-event. The company is also initiating a Phase 3 trial for its drug roluperidone.
Read more →NERV▲ +6.9%on this news
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Minerva Neurosciences is hosting a virtual KOL event on February 3, 2026, to discuss the negative symptoms of schizophrenia and the upcoming Phase 3 trial of roluperidone. Experts Gregory Strauss and Brian Kirkpatrick will address the challenges in assessing these symptoms and the potential of roluperidone as a treatment. This event highlights the ongoing unmet medical need for effective therapies targeting negative symptoms in schizophrenia.
Read more →NERVMinerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Minerva Neurosciences has appointed Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to its Board of Directors. Dr. Kaul is set to aid in the clinical development of roluperidone, particularly focusing on a Phase 3 trial for negative symptoms in schizophrenia. This appointment comes after the company's successful $200 million private placement aimed at funding this trial and related activities. The move is seen as a means to strengthen the company's clinical operations and address a significant unmet need in schizophrenia treatment.
Read more →NERVMinerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences reported its third quarter 2025 financial results, highlighting an $80 million financing to support its Phase 3 trial for roluperidone in treating schizophrenia. The company anticipates sufficient funds for the trial and NDA resubmission, despite a net loss of $2.7 million for the quarter. Cash reserves have decreased significantly compared to the previous year.
Read more →NERV▲ +141%on this news
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva Neurosciences has announced a financing deal worth up to $200 million to support the Phase 3 confirmatory trial of roluperidone, aimed at treating negative symptoms in schizophrenia patients. The funding includes an initial $80 million and potential additional funds based on milestone achievements. The company is also preparing for a resubmission of its New Drug Application (NDA) and a potential U.S. commercial launch, pending approval.
Read more →NERV▲ +141%on this newsshared move
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and
Minerva Neurosciences has announced a financing agreement for up to $200 million to support the development of roluperidone, targeting negative symptoms in schizophrenia patients. The funding will facilitate a Phase 3 confirmatory trial and the resubmission of its New Drug Application (NDA). The agreement includes an upfront payment, with additional funds contingent upon milestone achievements. Minerva also plans to enhance its board with experienced directors to bolster clinical operations. This financial backing aligns with recent FDA guidance on trial design, positioning Minerva towards a potential commercial launch.
Read more →NERVMinerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Minerva Neurosciences has announced an update regarding the FDA's requirement for a confirmatory study for roluperidone, aimed at treating negative symptoms of schizophrenia, following a previous Complete Response Letter. The company will conduct this trial, which may impact their previously planned New Drug Application resubmission. Financial results for Q2 2025 showed a reduced net loss compared to the same period last year, driven by lower research and development costs. However, Minerva is exploring strategic alternatives to enhance shareholder value, reflecting concerns related to its current cash position.
Read more →NERVMinerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences, Inc. has reported its financial results for the first quarter of 2025, highlighting positive developments such as regaining compliance with Nasdaq Listing Rules. The company experienced a notable reduction in net loss, reaching $3.8 million compared to $8.6 million in the same quarter last year. However, it continues to address regulatory feedback from the FDA regarding its New Drug Application for roluperidone while its cash position has slightly declined.
Read more →NERVMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
Minerva Neurosciences reported its financial results for the fourth quarter and fiscal year 2024, highlighting a significant decrease in net loss from the previous year. The company achieved a net income of $1.4 million for the fiscal year, largely due to an adjustment related to future royalties. However, the firm faces challenges, notably a Complete Response Letter from the FDA regarding its drug roluperidone, and a reduced cash position compared to the previous year. The company's research and development expenses decreased, reflecting some cost containment amid ongoing regulatory challenges.
Read more →NERVMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. reported its financial results for the third quarter of 2024, indicating a significant shift from a net loss in the previous year to a net income of $22.5 million. The company highlighted ongoing regulatory interactions with the FDA regarding its drug roluperidone, which received a Complete Response Letter. Despite the challenges posed by the FDA's feedback and a decline in cash reserves, the company successfully reduced operational expenses, leading to a more favorable financial outlook. Further details on their financial management and R&D expenditures were also provided.
Read more →NERV▲ +5%on this news
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. reported its financial results for the second quarter of 2024, showing a net loss of $8.2 million, an increase from the previous year's loss of $6.2 million. The company continues to engage with the FDA regarding its New Drug Application (NDA) for roluperidone after receiving a Complete Response Letter earlier this year. R&D expenses have risen significantly due to ongoing drug development efforts. Additionally, the company’s cash reserves have decreased notably, raising concerns about its financial stability moving forward.
Read more →NERVMinerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. reported its first quarter 2024 financial results, revealing a significant net loss of $8.6 million. The company is currently addressing concerns raised by the FDA in a Complete Response Letter related to its roluperidone NDA. A recent Phase 1b clinical trial displayed promising tolerance and safety results when roluperidone was administered with olanzapine. Despite increased expenses in research and development, Minerva continues to maintain a substantial cash position of approximately $34.9 million.
Read more →NERV▼ -58.8%on this news
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences has received a Complete Response Letter from the FDA concerning their New Drug Application for roluperidone, intended to treat negative symptoms of schizophrenia. The FDA pointed out several clinical deficiencies that must be addressed, including the need for additional studies to support the drug's safety and efficacy. The company has expressed disappointment but remains committed to collaborating with the FDA to explore next steps. The need for effective treatments for negative symptoms in schizophrenia is emphasized, as no approved therapies currently exist in the U.S.
Read more →NERV▼ -17.6%on this news· ran to -68% by day 3shared move
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
Minerva Neurosciences reported its financial results for the fourth quarter and fiscal year 2023. The company achieved a key milestone with the FDA's acceptance of its New Drug Application for roluperidone, potentially the first treatment for negative schizophrenia symptoms. The NDA review has a PDUFA date set for February 26, 2024. Despite an increase in cash reserves to $41 million, the company reported a net loss of $9 million in Q4 2023, up from $6.7 million the previous year.
Read more →NERVMinerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences reported its financial results for the third quarter of 2023, highlighting a net loss of $7.8 million. The company is currently working with the FDA on its New Drug Application for roluperidone, intended to treat negative symptoms of schizophrenia, with a key decision expected by February 26, 2024. Notably, Minerva's cash position has improved year-over-year, signaling stable financial operation amid ongoing expenses associated with regulatory reviews.
Read more →NERV▲ +9.1%on this news
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. reported its financial results for Q2 2023, highlighting a completed equity financing of $20 million and ongoing preparations for the FDA review of its NDA for roluperidone. The company is optimistic about its prospects, citing the potential of roluperidone to address negative symptoms of schizophrenia, an area with significant unmet needs. Financially, Minerva reported a net loss of $6.2 million for the quarter but improved its cash position to approximately $51.9 million as of June 30, 2023. The FDA has set a PDUFA goal date of February 26, 2024, for the review of roluperidone.
Read more →NERV▲ +69.3%on this news
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
Minerva Neurosciences has announced a $20 million private placement with Boehringer Ingelheim and Federated Hermes Kaufmann Funds, pricing the shares at a premium to market at $10 per share. The funds will support the potential U.S. approval, commercialization, and market launch of roluperidone, which is in development for treating negative symptoms of schizophrenia. The transaction is set to close by June 30, 2023, pending customary conditions. Notably, the securities will not be registered under the Securities Act at the time of sale.
Read more →NERV▼ -11.4%on this news· ran to -22% by day 1
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Minerva Neurosciences reported significant progress with its investigational drug, roluperidone, as the FDA filed the NDA for treating negative symptoms of schizophrenia. The PDUFA goal date is set for February 26, 2024. Financial performance showed reduced research and development expenses and a net loss of $7 million for the first quarter of 2023. These developments suggest an optimistic outlook for the company's future, although regulatory hurdles remain a concern.
Read more →NERV▲ +13.7%on this newsshared move
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences has received confirmation from the FDA regarding the acceptance of its New Drug Application (NDA) for roluperidone, aimed at treating negative symptoms in schizophrenia. The application has been granted a standard review with a PDUFA goal date set for February 26, 2024. However, the FDA has noted potential review issues which may impact the approval timeline. Roluperidone is significant as it targets negative symptoms, a crucial area lacking effective treatments in the US.
Read more →NERVMinerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
Minerva Neurosciences, a clinical-stage biopharmaceutical company, announced it will release its first quarter 2023 financial results and business updates on May 15, 2023. A webcast will be held at 8:30 a.m. Eastern Time to discuss these results. The company is dedicated to developing treatments for central nervous system disorders, highlighting its ongoing commitment to addressing unmet medical needs in this area.
Read more →NERV▲ +34.3%on this news· ran to +65% by day 3
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia FDA grants appeal and files
Minerva Neurosciences has announced that the FDA has filed its New Drug Application (NDA) for roluperidone, aimed at treating negative symptoms in schizophrenia. This development follows an appeal concerning a previous refuse-to-file letter from the FDA addressing concerns brought up in 2022. The filing represents a crucial step towards potentially securing approval for the first treatment specifically targeting the negative symptoms experienced by many schizophrenia patients. Positive symptoms currently have no approved treatments, highlighting the innovative nature of this application.
Read more →NERV▲ +34.3%on this news· ran to +65% by day 3
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences announced the filing of a New Drug Application (NDA) for roluperidone with the FDA, aimed at treating negative symptoms in schizophrenia. This follows the FDA's appeal decision acknowledging previously cited issues during an earlier refuse-to-file response. The company emphasizes that there are currently no approved treatments for negative symptoms, indicating that this drug could revolutionize treatment and offer significant benefits to patients. Experts advocate for the importance of addressing negative symptoms, marking this application as a potential breakthrough in schizophrenia therapy.
Read more →NERV▼ -7.6%on this news
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
Minerva Neurosciences reported its financial results and business updates for the fourth quarter and year ended December 31, 2022. The company received a Refuse to File letter from the FDA regarding its NDA for the lead compound, roluperidone, which is intended to treat negative symptoms of schizophrenia. Despite improved financials, including a reduced net loss, Minerva faces regulatory challenges and ongoing discussions with the FDA about the drug's development path. The uncertainty surrounding the drug's approval and clinical efficacy poses significant risks for the company's future.
Read more →NERVMinerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
Minerva Neurosciences, Inc. plans to announce its fiscal year 2022 financial results and business updates on March 8, 2023. A webcast will be held at 8:30 a.m. Eastern Time that day for a detailed discussion. The company is focused on developing therapies for central nervous system disorders, including its compounds for schizophrenia and Parkinson's disease. The archived webinar will be accessible on the company's website shortly after the live event.
Read more →NERV▲ +8.8%on this news
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
BURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial r
Read more →NERV▲ +6.5%on this news
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial resu
Read more →NERV▼ -69.5%on this news
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia BURLINGTON, Mass. October 17, 2022 (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage
Read more →NERVMinerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market BURLINGTON, Mass. September 9, 2022 (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous
Read more →NERV▲ +47.8%on this news· ran to +110% by day 3
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia WALTHAM, Mass. August 22, 2022 (Globe Newswire) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical compa
Read more →NERV▼ -23.9%on this news
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resu
Read more →NERVMinerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resul
Read more →NERV▲ +6.8%on this news
Disclaimer This presentation contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are stateme
Roluperidone Update Webcast: Wednesday, April 13, 2022, at 11:00 ET To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 2489714. The live webcast can be accessed under "Events and Presentations" in the Investors and
Read more →NERVMinerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Com
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Webcast Wednesday, April 13, 2022 at 11am ET WALTHAM, Mass.,
Read more →NERVMinerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system disorders, today reported key business updates and financial
Read more →NERVMinerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve Everyday Functioning in Patients with Schizophrenia WALTHAM, Mass. February 2
Read more →NERVMinerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that results from the Phase 3 clinical
Read more →NERVForward-Looking Statement Safe-Harbor Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect manageme
Corporate Presentation January 2022 Forward-Looking Statement Safe-Harbor Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect management's expectations as o
Read more →NERVAbstract Objective: In a previous large multi-national trial, roluperidone (MIN-101) a compound with antagonistic properties for 5 HT2A, sigma2 and 1A-adrenergic receptors demonstrated statistically significant efficacy
3 Authors: Michael Davidson1,2 MD, Jay Saoud1 PhD, Corinne Staner3 MD, Nadine Noel3 PhD, Sandra Werner3 PhD, Elisabeth Luthringer3 RN, Philip Harvey PhD, Gregory Strauss PhD, Mark Weiser4MD, Remy Luthringer1 PhD Efficacy and safety of roluperidone for the treatment of negative
Read more →NERVMinerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders,
Read more →NERVMinerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission Mass. November 3, 2021 (Globe Newswire)
Read more →NERVMinerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U. S. Food and Drug Administr
Read more →NERVMinerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Announces Promotion of Geoff Race to President Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA Waltham, Mass.
Minerva Neurosciences Announces Promotion of Geoff Race to President Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Waltham, Mass. October 11, 2021 (Globe Newswire) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
Read more →NERVMinerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophren
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Se
Read more →NERVMinerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced results from a pivotal bioequivalence study
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES APPOINTMENT OF DR. RAMANA KUCHIBHATLA AS SENIOR VICE
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES APPOINTMENT OF DR. RAMANA KUCHIBHATLA AS SENIOR VICE PRESIDENT AND HEAD OF RESEARCH & DEVELOPMENT Dr. Jay
Read more →NERVMinerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud’s retirement and transi
Read more →NERVMinerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resu
Read more →NERVMinerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences to Present at JMP Securities Life Sciences Conference
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in
Read more →NERVMinerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in
Read more →NERVMinerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psycho
Read more →NERVMinerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension
Continuous improvement in negative symptoms as measured by Positive and Negative Syndrome Scale (PANSS) Marder Negative Symptom Factor Score (NSFS) observed over one year (12-week double-blind and 40-week open-label periods) in patients receiving both 64 mg and 32 mg doses Conti
Read more →NERVMinerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021
WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021 Minerva’s royalty interest in seltorexant acquired by Royalty Pharma for an upfront payment of $60 million and up to $95 million in additi
Read more →NERVMinerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial result
Read more →NERVMINERVA FINAL DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline – NERV
WHY: NEW YORK, Feb. 06, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the "Class Period"), of the important Febr
Read more →NERVMinerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
WALTHAM, Mass. and NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up
Read more →NERV: William B. Boni Minerva Neurosciences, Inc. (617) 600-7376 Royalty Pharma plc (212) 883-2295 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE SALE OF SELTOREXANT ROYALTY FOR UP TO $155 MI
Contact : William B. Boni Minerva Neurosciences, Inc. (617) 600-7376 Royalty Pharma plc (212) 883-2295 MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE SALE OF SELTOREXANT ROYALTY FOR UP TO $155 MILLION Waltham, MA and New York, NY, January 19, 2021 Minerva Neuros
Read more →NERVMinerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
WALTHAM, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has received official meeting
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone Waltham, MA, December 1, 2020 Minerv
Read more →NERVMinerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference
WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in
Read more →NERVMinerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
WALTHAM, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resu
Read more →NERVMinerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
WALTHAM, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate i
Read more →NERVMinerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate i
Read more →NERVMinerva Neurosciences to Present at JMP Securities CNS Forum
WALTHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVMinerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resu
Read more →NERVMinerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES EXERCISES RIGHT TO OPT OUT OF AGREEMENT WITH JANSSEN FOR SELTO
VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. NEUROSCIENCES EXERCISES RIGHT TO OPT OUT OF AGREEMENT WITH JANSSEN FOR SELTOREXANT (MIN-202) Waltham, MA, July 1, 2020 Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical comp
Read more →NERVMinerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexant Corporate focus now on lead product, roluperidone, in Phase 3 development WALTHAM, Mass.,
Read more →NERVForward-Looking Statement Safe-Harbor This presentation contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-loo
ROLUPERIDONE: Topline results from the Phase 3 trial: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients with Negative Symptoms of Schizophrenia
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF ROLUPERIDONE (MIN-101)
VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. NEUROSCIENCES ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF ROLUPERIDONE (MIN-101) FOR TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Waltham, MA, May 29, 2020 Minerva Neurosciences, Inc. (NASDAQ: NERV), a cl
Read more →NERVMinerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259, respectively), or the key secondary endpoint, the Personal and Social Performance Scale T
Read more →NERVMinerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resul
Read more →NERVMinerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020
WALTHAM, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial result
Read more →NERVAll trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Forward-Looking Statement Safe-Harbor This presentation contains forward-looking statements about
Roluperidone: A potential novel mechanism to treat the negative symptoms of schizophrenia William Carpenter MD John Kane MD Steven Marder MD Ofer Agid MD Remy Luthringer PhD Hosted by Minerva Neurosciences (Nasdaq: NERV) Tuesday, March 31, 2020 Exhibit 99.1 All trademarks, trad
Read more →NERVMINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
WALTHAM, Mass., March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central nervous system (CNS) disorders, today
Read more →NERVMINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT
WALTHAM, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, wishes to address a
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES REPORTS FISCAL 2019 FOURTH QUARTER AND YEAR END FINANCIAL RESUL
VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. NEUROSCIENCES REPORTS FISCAL 2019 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND BUSINESS UPDATES Company confirms timing of expected top-line results from Phase 3 roluperidone trial in Q2 2020 Mana
Read more →NERVMinerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates
Company confirms timing of expected top-line results from Phase 3 roluperidone trial in Q2 2020 Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage bio
Read more →NERVMinerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020
WALTHAM, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial result
Read more →NERVMinerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today announced that
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 3 TRIAL OF
MINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 3 TRIAL OF ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Data readout expected in the second quarter of 2020 Waltham, MA, February 5, 2020 Minerva Neurosciences, Inc. (NASDAQ: NER
Read more →NERVMinerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central nervous system (CNS) disorders, today a
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF PATIENT SCREENING IN PHASE 3 TRIAL OF
VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. NEUROSCIENCES ANNOUNCES COMPLETION OF PATIENT SCREENING IN PHASE 3 TRIAL OF ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Top-line results expected in the second quarter of 2020 W
Read more →NERVMinerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central nervous system (CNS) disorders, today a
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES REPORTS TOPLINE RESULTS FROM PHASE 2B TRIAL OF MIN-117 IN MAJO
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES REPORTS TOPLINE RESULTS FROM PHASE 2B TRIAL OF MIN-117 IN MAJOR DEPRESSIVE Waltham, MA, December 18, 2019
Read more →NERVMinerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints MIN-117 was generally well-tolerated with a safety profile comparable to placebo Company to host conference call at 5:00 p.m. today (dial-in information below) WALTHAM, Mass., Dec. 18, 2019 (GLO
Read more →NERVMinerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVMinerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resu
Read more →NERVMinerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
WALTHAM, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Announces Update for Three Clinical Trials
WALTHAM, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced an update on three clinical-stage prog
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES UPDATE FOR THREE CLINICAL TRIALS Company to host con
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES UPDATE FOR THREE CLINICAL TRIALS Company to host conference call at 8:30 a.m. today (dial-in information bel
Read more →NERVMinerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET
WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will hold a conference call and live audio webcast on
Read more →NERVCatalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone WALTHAM, Mass. and SOMERSET, N.Y.
Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone WALTHAM, Mass. and SOMERSET, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the deve
Read more →NERVMinerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive disorder (MDD) and insomnia Patient enrollment progresses in pivotal Phase 3 trial of
Read more →NERVMinerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019
WALTHAM, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia WALTHAM, Mass., June 24, 2019 (GLOBE NEWSWIRE) Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical com
Read more →NERVMinerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific orexin-2 receptor antagonist for the treatment of insomnia Key Opinion Leaders, Dr. T
Read more →NERVMinerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
WALTHAM, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVMinerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs WALTHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) Minerva Neurosciences, Inc. (NASDAQ: NE
Read more →NERVMinerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resul
Read more →NERVMinerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial result
Read more →NERVMinerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV)
Read more →NERVMinerva Neurosciences to Host Webcast Event on Schizophrenia
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -
Read more →NERVMinerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia disorder Five key data readouts expected in 2019 Management to host conference cal
Read more →NERVMinerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019
WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial result
Read more →NERVMinerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
WALTHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the filing of a U.S. patent applicatio
Read more →NERVMinerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVMinerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe and well tolerated with no significant changes in cardiac repolarization and QTc
Read more →NERVMinerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in C
Read more →NERVMinerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVMinerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CN
Read more →NERVMinerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
Management to host conference call WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced th
Read more →NERVMinerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
WALTHAM, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced findings from a recent pre-clinical stu
Read more →NERVMinerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resu
Read more →NERVMinerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Devin W. Smith as Se
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ELECTS JERYL HILLEMAN TO BOARD OF DIRECTORS Waltham, MA
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ELECTS JERYL HILLEMAN TO BOARD OF DIRECTORS Waltham, MA, July 17, 2018 Minerva Neurosciences, Inc. (NASDAQ: NERV), a c
Read more →NERVMinerva Neurosciences Elects Jeryl Hilleman to Board of Directors
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the B
Read more →NERVMINERVA NEUROSCIENCES, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN (Amended and Restated as of
MINERVA NEUROSCIENCES, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN (Amended and Restated as of April 21, 2018) 1.1 PURPOSE OF THE PLAN This Amended and Restated 2013 Equity Incentive Plan (the Plan ) is intended to promote the interests of Minerva Neurosciences, In
Read more →NERVMinerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the J
Read more →NERVMinerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial result
Read more →NERVMinerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the screening of the first patient in
Read more →NERVMinerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
WALTHAM, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader (KOL) meeting
Read more →NERVMinerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Minerva
Read more →NERVMinerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR Waltham, MA, February 5, 2018 Minerva N
Read more →NERVMinerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Dr. Rémy Luthringer has been appointed as Executi
Read more →NERVAll trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Forward Looking Statement Safe Harbor 2 This presentation contains forward looking statements abou
Animal models (non human primates): Effect of treatment on abnormal involuntary movements scale (AIMS) 29 Clear MPTP induced increase in AIMS scores Scores in MIN 301 treated animals lower during low MPTP ( 1 mg/kg) induction as compared to placebo Saline MIN 301 Start MPTP 1 mg
Read more →NERVMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in
Read more →NERVMinerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
Multi-center, international trial targets significant unmet need for which no treatments are approved Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe WALTHAM, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES NAMES RICHARD RUSSELL PRESIDENT Waltham, MA
VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. NEUROSCIENCES NAMES RICHARD RUSSELL PRESIDENT Waltham, MA, December 11, 2017 Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapie
Read more →NERVMinerva Neurosciences Names Richard Russell President
WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Rick Russell as Pres
Read more →NERVMinerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of William F. Doyle and Ha
Read more →NERVMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
WALTHAM, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in
Read more →NERVMinerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017
WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2
Read more →NERVMinerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates
WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resul
Read more →NERVMinerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy
WALTHAM, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Dr. Justine Lalonde,
Read more →NERVMinerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017
WALTHAM, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Dr. Jay B. Saoud as
Read more →NERVMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES EUROPEAN COMMISSION APPROVAL OF AMENDMENT OF MIN-202
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES EUROPEAN COMMISSION APPROVAL OF AMENDMENT OF MIN-202 AGREEMENT WITH JANSSEN Proceeds from amended agreement, combined wi
Read more →NERVMinerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen
Proceeds from amended agreement, combined with finances raised from recent public stock offering and current financial resources, significantly extend Minerva cash runway Combined proceeds are expected to support anticipated data readouts from five planned clinical trials with t
Read more →NERVMinerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
FDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second half of 2017 Amended agreement with Janssen supports dual focus of clinical developme
Read more →NERVMinerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES DEPARTURE OF DIRECTORS Waltham, MA
MINERVA NEUROSCIENCES ANNOUNCES DEPARTURE OF DIRECTORS Waltham, MA, July 24, 2017 Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the resign
Read more →NERVMinerva Neurosciences Announces Departure of Directors
WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the resignation of two members of its board o
Read more →NERVMinerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public offering of 5,750,000 shares of its common stock, including 750,000 shares sold
Read more →NERVMinerva Neurosciences Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $7.75 per sh
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES, INC. TO OFFER COMMON SHARES Waltham, MA
VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. NEUROSCIENCES, INC. TO OFFER COMMON SHARES Waltham, MA, June 27, 2017 Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and s
Read more →NERVMinerva Neurosciences, Inc. to Offer Common Shares
WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 5,000,000 shares of its common stock in an underwritten public offering pursuant to an existing
Read more →NERVMinerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia
New formulation observed to improve safety margin while offering bioequivalent exposure to prior formulation Company to proceed with initiation of Phase 3 trial on schedule in second half of 2017 CMC scale-up work for NDA preparation initiated WALTHAM, Mass., June 22, 2017 (GL
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA ANNOUNCES AMENDED AGREEMENT FOR MIN-202 IN INSOMNIA Minerva to gain global s
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA ANNOUNCES AMENDED AGREEMENT FOR MIN-202 IN INSOMNIA Minerva to gain global strategic control over development of MIN-202 for insomni
Read more →NERVMinerva Announces Amended Agreement for MIN-202 in Insomnia
Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by an affiliate of Janssen (approximately 3.9 million shares representing approximat
Read more →NERVMinerva Neurosciences to Present at Jefferies 2017 Healthcare Conference on June 6, 2017
WALTHAM, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the J
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA ANNOUNCES OUTCOME OF END-OF-PHASE 2 MEETING WITH FDA Pivotal Phase 3 trial de
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA ANNOUNCES OUTCOME OF END-OF-PHASE 2 MEETING WITH FDA Pivotal Phase 3 trial design to include monotherapy administration of MIN-101 an
Read more →NERVMinerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
Advancing a new potential therapeutic paradigm for the treatment of negative symptoms, a key unmet need in schizophrenia and other brain diseases Company to host conference call on May 16, 2017 at 10:30 a.m. eastern time WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Minerva
Read more →NERVMinerva Announces Outcome of End-of-Phase 2 Meeting With FDA
Pivotal Phase 3 trial design to include monotherapy administration of MIN-101 and primary endpoint of improvement in negative symptoms of schizophrenia Planned initiation of MIN-101 Phase 3 development in second half of 2017 WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Foll
Read more →NERVMinerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial result
Read more →NERVMinerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
WALTHAM, Mass., March 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today announced the
Read more →NERVMinerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates
Multiple positive data readouts during 2016 provide foundation for initiation of advanced clinical trials with three product candidates in 2017 Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosci
Read more →NERVMinerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017
WALTHAM, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017
WALTHAM, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Cowen and C
Read more →NERVThis presentation contains certain forward-looking statements about Minerva Neurosciences that are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation
Innovation to change the way we treat CNS disease February / March 2017 Nasdaq: NERV Exhibit 99.1 This presentation contains certain forward-looking statements about Minerva Neurosciences that are intended to be covered by the safe harbor for "forward-looking statements" provi
Read more →NERVMinerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia
WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will host a Research and Development Day to highlight u
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE ADDITIONAL DATA ANALYSES FROM PHASE IIB TRIAL OF MIN-101 IN SCHIZOPHRENIA UNDERSCORE
ADDITIONAL DATA ANALYSES FROM PHASE IIB TRIAL OF MIN-101 IN SCHIZOPHRENIA UNDERSCORE BENEFIT IN MULTIPLE MEASUREMENTS OF January 20, 2016 Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat cent
Read more →NERVMinerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer
WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Michael Davidson, M.
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES CLINICAL DATA FEATURED AT THE AMERICAN COLLEGE OF NEUROPSYCHOPH
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES CLINICAL DATA FEATURED AT THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING Oral presentation highlights
Read more →NERVMinerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting
Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial Data also presented from Phase IIA trials with MIN-101 and MIN-117 WALTHAM, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) --
Read more →NERVMinerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016
WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2
Read more →NERVMinerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial resul
Read more →NERVMinerva Neurosciences to Report Third Quarter 2016 Financial Results and Business Updates on November 3, 2016
WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES POSITIVE DATA FROM SIX-MONTH EXTENSION OF PHASE IIB T
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES POSITIVE DATA FROM SIX-MONTH EXTENSION OF PHASE IIB TRIAL OF MIN-101 MONOTHERAPY IN SCHIZOPHRENIA Data show continuous i
Read more →NERVMinerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia
WALTHAM, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced data from the 24-week open-label extens
Read more →NERVMinerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting
WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the acceptance of four abstracts for pr
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES PROVIDES UPDATE ON MIN-101 AND MIN-117 CLINICAL PROGRAMS Last
VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. MINERVA NEUROSCIENCES PROVIDES UPDATE ON MIN-101 AND MIN-117 CLINICAL PROGRAMS Last patient completes extension phase of Phase IIb trial with MIN-101 Company receives FDA acceptance of Investigational N
Read more →NERVMinerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs
Last patient completes extension phase of Phase IIb trial with MIN-101 Company receives FDA acceptance of Investigational New Drug Application for MIN-117 WALTHAM, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceu
Read more →NERVMinerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016
WALTHAM, Mass., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVMinerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major depressive disorder WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Minerva Neuroscienc
Read more →NERVMinerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016
WALTHAM, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Set to Join Russell 3000 and Russell 2000 Indexes
WALTHAM, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced that the Company has been added to the Russell 3000® Index and the Russell 2000® Index. Trading in these newly reconstituted in
Read more →NERVMinerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVJune 2016 Innovative CNS therapies to address unmet medical needs This presentation contains certain forward-looking statements about Minerva Neurosciences that are intended to be covered by the safe harbor for "forward-
June 2016 Innovative CNS therapies to address unmet medical needs This presentation contains certain forward-looking statements about Minerva Neurosciences that are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Li
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
Corp. Communications Minerva Neurosciences, Inc. MINERVA NEUROSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK WALTHAM, Mass., June 13, 2016 Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company, today announced its intention to off
Read more →NERVMinerva Neurosciences Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf reg
Read more →NERVMinerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES POSITIVE RESULTS FROM PHASE IIB TRIAL OF MIN-101 MON
Corp. Communications Minerva Neurosciences, Inc. MINERVA NEUROSCIENCES ANNOUNCES POSITIVE RESULTS FROM PHASE IIB TRIAL OF MIN-101 MONOTHERAPY IN SCHIZOPHRENIA MIN-101 meets primary and secondary endpoints Waltham, MA, May 26, 2016 Minerva Neurosciences, Inc. (NASDAQ: NERV),
Read more →NERVMinerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia
Statistically significant improvement in PANSS negative symptoms and total PANSS scores observed MIN-101 shown to be statistically superior on key secondary endpoints Effect of MIN-101 demonstrated to be specific for negative symptoms and not secondary to improvement in other s
Read more →NERVMinerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder
Reduction in depressive symptoms demonstrated Good tolerability and safety profile observed Positive effect on sleep architecture shown Differentiated mechanism of action WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-st
Read more →NERVMinerva Neurosciences Reports First Quarter 2016 Financial Results and Business Updates
Positive top line results of trials with MIN-202 highlight first quarter Last patient visits completed in trials with MIN-101 and MIN-117; data expected in second quarter WALTHAM, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-sta
Read more →NERVMinerva Neurosciences to Report First Quarter 2016 Financial Results and Business Updates on May 3, 2016
WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Reports Fiscal 2015 Fourth Quarter and Year End Financial Results and Business Updates
Clinical trial advancements during 2015 support multiple top line data readouts in first half of 2016 Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stag
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES POSITIVE TOP LINE RESULTS FROM PHASE IB CLINICAL TRIA
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES POSITIVE TOP LINE RESULTS FROM PHASE IB CLINICAL TRIAL IN MAJOR DEPRESSIVE DISORDER WITH MIN-202 Treatment with selectiv
Read more →NERVMinerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202
Treatment with selective orexin-2 receptor antagonist observed to be well tolerated and to improve symptoms of depression, independent from its effect on sleep WALTHAM, Mass., March 11, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharm
Read more →NERVMinerva Neurosciences to Report Fiscal 2015 Fourth Quarter and Year End Financial Results and Business Updates on March 14, 2016
WALTHAM, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results
Read more →NERVMinerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder
WALTHAM, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the completion of patient enrollment in
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE IIA TRIAL
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE IIA TRIAL OF MIN-117 IN MAJOR DEPRESSIVE DISORDER Waltham, MA, February 22, 2
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES TOP LINE DATA FROM MIN-202 PHASE I CLINICAL STUDY IN
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES TOP LINE DATA FROM MIN-202 PHASE I CLINICAL STUDY IN JAPANESE PATIENTS Treatment with selective orexin-2 receptor an
Read more →NERVMinerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients
WALTHAM, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders, today announced top line results from a Phase I clinical tri
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES FAVORABLE TOP LINE RESULTS FROM MIN-202 PHASE 2A CLIN
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES FAVORABLE TOP LINE RESULTS FROM MIN-202 PHASE 2A CLINICAL TRIAL IN INSOMNIA DISORDER Consistent improvements observed wi
Read more →NERVMinerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder
WALTHAM, Mass., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders, today announced favorable top line results from a Phase 2A c
Read more →NERVMinerva Neurosciences Announces Update on MIN-101 Clinical Development Program
WALTHAM, Mass., Dec. 29, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administrat
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES ANNOUNCES UPDATE ON MIN-101 CLINICAL DEVELOPMENT PROGRAM Enrol
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES ANNOUNCES UPDATE ON MIN-101 CLINICAL Enrollment completed in European Phase IIb trial and Investigational New Drug (I
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA ACHIEVES ENROLLMENT TARGET IN PHASE IIB TRIAL WITH MIN-101 Waltham, MA
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA ACHIEVES ENROLLMENT TARGET IN PHASE IIB TRIAL WITH MIN-101 Waltham, MA, December 18, 2015 Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical
Read more →NERVMinerva Achieves Enrollment Target in Phase IIb Trial With MIN-101
WALTHAM, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has met its enrollment target o
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA PROVIDES YEAR-END UPDATE ON CLINICAL TRIALS WITH THREE CENTRAL NERVOUS SYSTE
MINERVA PROVIDES YEAR-END UPDATE ON CLINICAL TRIALS WITH THREE CENTRAL NERVOUS SYSTEM PRODUCT CANDIDATES Patient enrollment progress during 2015 confirms timeline expectations for topline data availability from four trials in first half of 2016 Waltham, MA, December 9, 2015 M
Read more →NERVMinerva Provides Year-End Update on Clinical Trials With Three Central Nervous System Product Candidates
WALTHAM, Mass., Dec. 9, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided a year-end update on clinical trials test
Read more →NERVMinerva Neurosciences to Present at Jefferies 2015 London Healthcare Conference on November 18, 2015
WALTHAM, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVMinerva Neurosciences Reports Third Quarter 2015 Financial Results and Business Updates
Clinical Trials Remain on Track for Data Readouts in the First Half of 2016 Dr. David Kupfer Joins Board of Directors Management to Host Conference Call Today at 8:30 a.m. Eastern Time WALTHAM, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV),
Read more →NERVMinerva Neurosciences Announces Appointment of Dr. David Kupfer to its Board of Directors
Minerva Neurosciences Announces Appointment of Dr. David Kupfer to its Board of Directors WALTHAM, Mass., November 2, 2015 Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous sys
Read more →NERVMinerva Neurosciences to Report Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015
WALTHAM, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release third quarter 2015
Read more →NERVWilliam B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES PROVIDES UPDATE ON CLINICAL DEVELOPMENT PROGRAM WITH MIN-202, S
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES PROVIDES UPDATE ON CLINICAL DEVELOPMENT PROGRAM WITH MIN-202, SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST Patient recruitme
Read more →NERVMinerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist
WALTHAM, Mass., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today provided an update on two ongoing cli
Read more →NERVMinerva Neurosciences to Present at Baird 2015 Healthcare Conference on September 9, 2015
WALTHAM, Mass., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the
Read more →NERVMinerva Neurosciences Reports Second Quarter 2015 Financial Results and Business Updates
Opening of clinical sites in six countries builds momentum in MIN-101 Phase IIb schizophrenia trial First patient dosed in Phase IIa study with MIN-117 in major depressive disorder First patient dosed in Phase Ib study with MIN-202 as adjunctive treatment for major depressive d
Read more →NERVMinerva Neurosciences to Report Second Quarter 2015 Financial Results and Host Conference Call on August 5, 2015
WALTHAM, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will release second
Read more →NERV: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 FOR IMMEDIATE RELEASE MINERVA NEUROSCIENCES PROVIDES UPDATE ON MIN-202, SELECTIVE OREXIN-2 RECEPTOR ANTAGO
Contact : William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 MINERVA NEUROSCIENCES PROVIDES UPDATE ON MIN-202, SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST Data in Insomnia Presented by Janssen at SLEEP 2015 IND Now in Ef
Read more →NERVMinerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist
Data in Insomnia Presented by Janssen at SLEEP 2015 IND Now in Effect to Expand Clinical Testing into Adjunctive Major Depressive Disorder WALTHAM, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company foc
Read more →NERVMinerva Neurosciences to Present at Upcoming Investor Conferences in June
WALTHAM, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases and disorders, today announced that it will par
Read more →NERVMinerva Neurosciences Announces Appointment of Dr. Fouzia Laghrissi-Thode to Its Board of Directors
WALTHAM, Mass., May 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced the appointment of Fouzia Laghrissi-Thode, M.D. to its board of directors, effective immediately. "Dr. Laghrissi-Thode brings extensive experience in global pharmaceutical
Read more →NERVMinerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates
MIN-101 Phase 2b trial for schizophrenia on track with enrollment underway; new regulatory approvals to conduct trials in Europe MIN-117 Phase 2a study in Major Depressive Disorder (MDD) on track and expected to begin enrollment in second quarter; additional study arm planned M
Read more →NERVMinerva Neurosciences to Host First Quarter 2015 Financial Results Webcast and Conference Call
WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases and disorders, today announced that it will r
Read more →NERVMinerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results MIN-101 Phase 2b trial for schizophrenia on track Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD pati
Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results MIN-101 Phase 2b trial for schizophrenia on track Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 Company advancin
Read more →NERVMinerva Neurosciences to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call
WALTHAM, Mass., March 19, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat Central Nervous System (CNS) diseases and disorders, today announced that it will r
Read more →NERVMinerva Neurosciences Completes Private Placement, Raises $31 Million
WALTHAM, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced that it has closed the private placement announced on March 13, 2015. Investors in the private placement included Federated Investors, Inc., Highland Capital, Perceptive A
Read more →NERVMinerva Neurosciences Announces $31 Million Financing
WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced that it will raise approximately $31 million of gross proceeds in a private placement offering to several institutional investors, including 6,281,661 shares of common sto
Read more →NERVAll trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Forward Looking Statement Safe Harbor 2 This presentation contains certain forward looking stateme
Thereafter, the AIMS scores of both groups were found to be equal. A : saline control B : MIN 301 analog 50 PRIMOMED Project: MIN 301 Analog Results Effect of Treatment on Locomotor Activity (Bungalow Test) A : saline control B : MIN 301 analog Start MPTP 1 mg / kg Increase MPTP
Read more →NERVMINERVA NEUROSCIENCES REPORTS POSITIVE PHASE 1 DATA WITH MIN-202, SELECTIVE OREXIN-2 ANTAGONIST FOR TREATMENT OF SLEEP DISORDERS INCLUDING PRIMARY AND COMORBID INSOMNIA Preliminary results provide a
MINERVA NEUROSCIENCES REPORTS POSITIVE PHASE 1 DATA WITH MIN-202, SELECTIVE OREXIN-2 ANTAGONIST FOR TREATMENT OF SLEEP DISORDERS INCLUDING PRIMARY AND COMORBID INSOMNIA Preliminary results provide additional support for progression of MIN-202 into next stage of clinical develo
Read more →NERVMinerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
Preliminary results provide additional support for progression of MIN-202 into next stage of clinical development. Minerva developing MIN-202 in collaboration with Janssen. WALTHAM, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announce
Read more →NERVMINERVA NEUROSCIENCES ANNOUNCES $15 MILLION DEBT FACILITY WITH OXFORD FINANCE LLC AND SILICON VALLEY BANK Funding supports Minerva continuing to advance the clinical program for MIN-101, the company
MINERVA NEUROSCIENCES ANNOUNCES $15 MILLION DEBT FACILITY WITH OXFORD FINANCE LLC AND SILICON VALLEY BANK Funding supports Minerva continuing to advance the clinical program for MIN-101, the company s investigational compound in development for treatment of schizophrenia WALT
Read more →NERVMinerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank
WALTHAM, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced it has entered into a $15 million debt facility with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB). The financing positions Minerva to broaden and advance the c
Read more →NERVMinerva Neurosciences Reports Positive Data Showing an Analog of Minerva s MIN-301 Compound Improves Symptoms of Parkinson s Disease in Primates Results provide further support for research involving use of neuregulin-1
Minerva Neurosciences Reports Positive Data Showing an Analog of Minerva s MIN-301 Compound Improves Symptoms of Parkinson s Results provide further support for research involving use of neuregulin-1 compounds in treatment of Parkinson s and other neurodegenerative disorders W
Read more →NERVMINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF DEVELOPMENT AND FINAL SELECTION OF ONCE-DAILY DOSE FORMULATION OF MIN-101 FOR ITS SCHIZOPHRENIA PROGRAM New formulation to be used in planned Phase 2b clinical trial has been
MINERVA NEUROSCIENCES ANNOUNCES COMPLETION OF DEVELOPMENT AND FINAL SELECTION OF ONCE-DAILY DOSE FORMULATION OF MIN-101 FOR ITS SCHIZOPHRENIA PROGRAM New formulation to be used in planned Phase 2b clinical trial has been developed to offer improved safety, tolerability and pha
Read more →NERVMINERVA NEUROSCIENCES APPOINTS DR. REMY LUTHRINGER AS CEO Waltham, MA (
MINERVA NEUROSCIENCES APPOINTS DR. REMY LUTHRINGER AS CEO Waltham, MA (November 25, 2014) Minerva Neurosciences, Inc. (NASDAQ: NERV), today announced the appointment of Remy Luthringer, Ph.D., president and chief scientific officer of Minerva, to the additional post of chief ex
Read more →NERVMinerva Neurosciences Appoints Dr. Remy Luthringer as CEO
WALTHAM, Mass., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), today announced the appointment of Remy Luthringer, Ph.D., president and chief scientific officer of Minerva, to the additional post of chief executive officer of the company, replacing R
Read more →NERVMinerva Neurosciences Reports Third Quarter 2014 Financial Results Advanced Lead Compound MIN-101 in Once-daily Formulation with Topline Results Expected in 4Q14; Phase 2b Study Expected to be Submitted in 4Q14 and Enrol
Minerva Neurosciences Reports Third Quarter 2014 Financial Results Advanced Lead Compound MIN-101 in Once-daily Formulation with Topline Results Expected in 4Q14; Phase 2b Study Expected to be Submitted in 4Q14 and Enrollment Expected to Begin in 1H15 Phase 1 Bioavailability S
Read more →NERVMinerva Neurosciences to Host Third Quarter 2014 Financial Results Webcast and Conference Call
WALTHAM, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that it will release third quarter financial results after market close on T
Read more →NERVMinerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial
CAMBRIDGE, Mass., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that the U.S. Food and Drug Administration has completed its review of th
Read more →NERVMinerva Neurosciences to Present at Baird 2014 Health Care Conference
CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Rogerio Vivaldi, president and chief executive officer of Minerva, wi
Read more →NERVMinerva Neurosciences Reports Second Quarter 2014 Financial Results Advanced Lead Compound MIN-101 in Phase 2 Studies for Schizophrenia and Clinical Development of MIN-202 in Insomnia Management to host conference call t
Minerva Neurosciences Reports Second Quarter 2014 Financial Results Advanced Lead Compound MIN-101 in Phase 2 Studies for Schizophrenia and Clinical Development of MIN-202 in Insomnia Management to host conference call today at 4:30 p.m. ET CAMBRIDGE, MA (August 7, 2014) Miner
Read more →NERVMinerva Neurosciences to Host Second Quarter 2014 Financial Results Webcast and Conference Call
CAMBRIDGE, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that it will release second quarter financial results after market close o
Read more →NERVMinerva Neurosciences, Inc. (NASDAQ: NERV) to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, July 3, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neurosychiatric diseases, will visit the NASDAQ MarketS
Read more →Competitive Position
How NERV ranks across every disease it competes inCompetitive Position is a premium feature
See how NERV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial